A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

The new version of CAR-T therapy has shown the ability to effectively destroy cancer cells in mice without suppressing the ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain hesitant on whether its efficacy outweighs the possible risks, according to ...

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s own immune system ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...